Eplontersen Sodium

Summary

Eplontersen Sodium (CHEMBL4594335) is an approved oligonucleotide; indicated across 3 conditions including familial amyloid neuropathy and polyneuropathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligonucleotide
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594335
Name	Eplontersen Sodium
Type	Oligonucleotide
Max phase	4

Also known as: AKCEA-TTR-LRX SODIUM, Eplontersen sodium, ION-682884 ICOSASODIUM SALT, ION-682884 SODIUM, IONIS-TTR-LRX SODIUM, ISIS-682884, Wainua, Wainua (autoinjector), EPLONTERSEN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
familial amyloid neuropathy	4	MONDO:0007100	EFO:0004129
polyneuropathy	4	MONDO:0001824	EFO:0009562
amyloidosis	1	MONDO:0019065	EFO:1001875

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).